pifithrin has been researched along with Cancer of Ovary in 5 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " We explored the effect of the combination of the histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in ovarian carcinoma cell lines, including the IGROV-1 cell line and two p53 mutant platinum-resistant sublines (IGROV-1/OHP and IGROV-1/Pt1)." | 7.78 | Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. ( Benedetti, V; Cincinelli, R; Corna, E; De Cesare, M; Gatti, L; Perego, P; Zaffaroni, N; Zunino, F, 2012) |
| " We explored the effect of the combination of the histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in ovarian carcinoma cell lines, including the IGROV-1 cell line and two p53 mutant platinum-resistant sublines (IGROV-1/OHP and IGROV-1/Pt1)." | 3.78 | Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. ( Benedetti, V; Cincinelli, R; Corna, E; De Cesare, M; Gatti, L; Perego, P; Zaffaroni, N; Zunino, F, 2012) |
| "Pifithrin-alpha did not enhance the apoptotic response after p53 down-regulation." | 1.35 | Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. ( Zuco, V; Zunino, F, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zuco, V | 2 |
| Zunino, F | 3 |
| Christodoulou, MS | 1 |
| Colombo, F | 1 |
| Passarella, D | 1 |
| Ieronimo, G | 1 |
| De Cesare, M | 2 |
| Gatti, L | 1 |
| Benedetti, V | 1 |
| Corna, E | 1 |
| Cincinelli, R | 1 |
| Zaffaroni, N | 1 |
| Perego, P | 1 |
| Walton, MI | 1 |
| Wilson, SC | 1 |
| Hardcastle, IR | 1 |
| Mirza, AR | 1 |
| Workman, P | 1 |
| Fraser, M | 1 |
| Chan, SL | 1 |
| Chan, SS | 1 |
| Fiscus, RR | 1 |
| Tsang, BK | 1 |
5 other studies available for pifithrin and Cancer of Ovary
| Article | Year |
|---|---|
Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis.
Topics: Apoptosis; Benzothiazoles; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Fibroblasts; | 2008 |
Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors.
Topics: Animals; Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Disease Models, Animal; Female; Ge | 2011 |
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X | 2012 |
An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines.
Topics: Animals; Benzothiazoles; Cell Cycle; Cell Line, Tumor; Cells, Cultured; Colonic Neoplasms; Female; F | 2005 |
Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells.
Topics: Adenoviridae; Apoptosis; Atrial Natriuretic Factor; bcl-2-Associated X Protein; Benzothiazoles; Casp | 2006 |